Using pharmacogenetics to understand adverse drug reactions in children | Zendy

Kaitlyn Shaw | Zendy; Ursula Amstutz | Zendy; Bruce Carleton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Using pharmacogenetics to understand adverse drug reactions in children

Author(s) -

Kaitlyn Shaw,

Ursula Amstutz,

Bruce Carleton

Publication year - 2011

Publication title -

paediatrics and child health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.55

H-Index - 43

eISSN - 1918-1485

pISSN - 1205-7088

DOI - 10.1093/pch/16.9.537

Subject(s) - ototoxicity , medicine , chemotherapy , cisplatin , methotrexate , pharmacogenetics , adverse effect , drug , adverse drug reaction , drug reaction , osteosarcoma , doxorubicin , hearing loss , pharmacotherapy , chemotherapeutic drugs , oncology , surgery , intensive care medicine , pharmacology , audiology , pathology , genotype , gene , biochemistry , chemistry

Two patients undergo chemotherapy for osteosarcoma of the right proximal tibia. The patients are the same age, were diagnosed within two years of one another, and received identical chemotherapy regimens consisting of cisplatin, doxorubicin and methotrexate. Treatment was successful – both patients are alive and well. However, after only two cycles of chemotherapy, one patient developed bilateral hearing loss with a progressive decline in audiological function, while the other patient’s hearing remained unimpaired. Ototoxicity is a well-characterized adverse drug reaction (ADR) to cisplatin, but why two patients who are so alike can experience profoundly different outcomes is perplexing. Heterogeneity of drug response is a common issue encountered in clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research